AU745790B2 - Methods for treating inflammation and inflammatory diseases using pADPRT inhibitors - Google Patents

Methods for treating inflammation and inflammatory diseases using pADPRT inhibitors Download PDF

Info

Publication number
AU745790B2
AU745790B2 AU74926/98A AU7492698A AU745790B2 AU 745790 B2 AU745790 B2 AU 745790B2 AU 74926/98 A AU74926/98 A AU 74926/98A AU 7492698 A AU7492698 A AU 7492698A AU 745790 B2 AU745790 B2 AU 745790B2
Authority
AU
Australia
Prior art keywords
amino
lps
compound
inh
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU74926/98A
Other languages
English (en)
Other versions
AU7492698A (en
Inventor
Ernest Kun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octamer Inc
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/855,616 external-priority patent/US5908861A/en
Application filed by Octamer Inc filed Critical Octamer Inc
Publication of AU7492698A publication Critical patent/AU7492698A/en
Application granted granted Critical
Publication of AU745790B2 publication Critical patent/AU745790B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
AU74926/98A 1997-05-13 1998-05-13 Methods for treating inflammation and inflammatory diseases using pADPRT inhibitors Ceased AU745790B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/855,616 US5908861A (en) 1997-05-13 1997-05-13 Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US08/855616 1997-05-13
US09/056,396 US6303629B1 (en) 1997-05-13 1998-04-06 Methods for treating inflammation, inflammatory diseases, arthritis and stroke using pADPRT inhibitors
US09/056396 1998-04-06
PCT/US1998/010033 WO1998051308A1 (fr) 1997-05-13 1998-05-13 Procede de traitement de l'inflammation ou de maladies inflammatoires a l'aide d'inhibiteurs de poly-adp ribose polymerase

Publications (2)

Publication Number Publication Date
AU7492698A AU7492698A (en) 1998-12-08
AU745790B2 true AU745790B2 (en) 2002-03-28

Family

ID=26735288

Family Applications (2)

Application Number Title Priority Date Filing Date
AU74847/98A Abandoned AU7484798A (en) 1997-05-13 1998-05-13 Methods for treating inflammation, inflammatory diseases, arthritis and strok e using padprt inhibitors
AU74926/98A Ceased AU745790B2 (en) 1997-05-13 1998-05-13 Methods for treating inflammation and inflammatory diseases using pADPRT inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU74847/98A Abandoned AU7484798A (en) 1997-05-13 1998-05-13 Methods for treating inflammation, inflammatory diseases, arthritis and strok e using padprt inhibitors

Country Status (9)

Country Link
EP (1) EP1009404A4 (fr)
JP (1) JP4362638B2 (fr)
CN (1) CN1198614C (fr)
AU (2) AU7484798A (fr)
BR (1) BR9809115A (fr)
CA (1) CA2289119C (fr)
IL (1) IL132758A0 (fr)
NZ (1) NZ501650A (fr)
WO (2) WO1998051308A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL210415B1 (pl) 1999-01-11 2012-01-31 Agouron Pharma Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
JP2004528376A (ja) 2001-05-08 2004-09-16 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害薬としてのイソキノリノン誘導体
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
US20070015814A1 (en) * 2005-06-10 2007-01-18 Ernest Kun Parp Modulators and Treatment of Cancer
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
WO2008030887A2 (fr) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Procédés de conception d'inhibiteurs de parp et leurs utilisations
US7994222B2 (en) * 2006-09-05 2011-08-09 Bipar Sciences, Inc. Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
EA019833B1 (ru) 2007-01-22 2014-06-30 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
CN101809017A (zh) 2007-09-14 2010-08-18 阿斯利康(瑞典)有限公司 酞嗪酮衍生物
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
ES2532402T3 (es) 2008-06-26 2015-03-26 Resverlogix Corporation Métodos de preparación de derivados de quinazolinona
EP2346495B2 (fr) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Formulation pharmaceutique 514
EP2377871A4 (fr) 2008-11-28 2012-07-25 Chugai Pharmaceutical Co Ltd Dérivé de 1-(2h)-isoquinolone
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
EP2408454A2 (fr) 2009-03-18 2012-01-25 Resverlogix Corp. Nouveaux agents anti-inflammatoires
JP5813626B2 (ja) 2009-04-22 2015-11-17 レスバーロジックス コーポレイション 新規抗炎症剤
KR102011641B1 (ko) 2011-11-01 2019-08-19 리스버로직스 코퍼레이션 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
WO2018237327A1 (fr) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. Procédés de traitement d'un glioblastome
WO2019067991A1 (fr) 2017-09-29 2019-04-04 Triact Therapeutics, Inc. Formulations d'iniparib et leurs utilisations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004663A1 (fr) 1989-09-26 1991-04-18 The Regents Of The University Of California 6-amino-1,2-benzopyrones utiles dans le traitement de maladies virales
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5516941A (en) 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5482975A (en) 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5473074A (en) 1991-10-22 1995-12-05 Octamer, Incorporated Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
DE4436127A1 (de) 1994-09-27 1996-03-28 Deutsches Rheumaforschungszent Verwendung von aromatischen Amiden und Säuren zur Behandlung von rheumatischen Erkrankungen
WO1996031206A2 (fr) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose
US10766598B2 (en) 2017-06-14 2020-09-08 The Boeing Company Wing-to-fuselage joints and aircraft including the same

Also Published As

Publication number Publication date
IL132758A0 (en) 2001-03-19
NZ501650A (en) 2001-11-30
CN1261278A (zh) 2000-07-26
CA2289119A1 (fr) 1998-11-19
AU7484798A (en) 1998-12-08
BR9809115A (pt) 2002-01-02
JP2002502367A (ja) 2002-01-22
EP1009404A1 (fr) 2000-06-21
EP1009404A4 (fr) 2009-07-01
WO1998051308A1 (fr) 1998-11-19
WO1998051307A1 (fr) 1998-11-19
CN1198614C (zh) 2005-04-27
AU7492698A (en) 1998-12-08
CA2289119C (fr) 2011-03-15
JP4362638B2 (ja) 2009-11-11

Similar Documents

Publication Publication Date Title
AU745790B2 (en) Methods for treating inflammation and inflammatory diseases using pADPRT inhibitors
US5908861A (en) Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
Jasiecka et al. Pharmacological characteristics of metamizole
Kang et al. Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages
Chan et al. Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis
Colell et al. Ganglioside GD3 enhances apoptosis by suppressing the nuclear factor‐κB‐dependent survival pathway
Rawls et al. Effects of opioids, cannabinoids, and vanilloids on body temperature
Lee et al. Inhibitory effects of a spinasterol glycoside on lipopolysaccharide-induced production of nitric oxide and proinflammatory cytokines via down-regulating MAP kinase pathways and NF-κB activation in RAW264. 7 macrophage cells
Zingarelli et al. Activator protein‐1 signalling pathway and apoptosis are modulated by poly (ADP‐ribose) polymerase‐1 in experimental colitis
BRPI0616344A2 (pt) mÉtodo para o tratamento de dependÊncia quÍmica e comportamental
AU2002255805A1 (en) Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
Guo et al. Fumigaclavine C ameliorates dextran sulfate sodium-induced murine experimental colitis via NLRP3 inflammasome inhibition
Jiang et al. CTRP1 prevents sepsis-induced cardiomyopathy via Sirt1-dependent pathways
KR100701539B1 (ko) 멜라가트란의 신규 용도
Busserolles et al. Protection against 2, 4, 6-trinitrobenzenesulphonic acid-induced colonic inflammation in mice by the marine products bolinaquinone and petrosaspongiolide M
Toth et al. Tumorigenic effect of 4-methylphenylhydrazine hydrochloride in Swiss mice
ES2274814T3 (es) Uso de compuestos carboxy tales como cloruro de 2(4-acetofenil) -2cloro-n-metil-etilamonio como agentes antiinflamatorios.
Rowe et al. The effect of fluoxetine on warfarin metabolism in the rat and man
Roth et al. Dose-dependent attenuation of lipopolysaccharide-fever by inhibitors of inducible nitric oxide-synthase in guinea pigs
Eski et al. Thalidomide decreases the plasma levels of IL-1 and TNF following burn injury: Is it a new drug for modulation of systemic inflammatory response
Alexandre-Moreira et al. LASSBio-468: a new achiral thalidomide analogue which modulates TNF-α and NO production and inhibits endotoxic shock and arthritis in an animal model
Abekawa et al. Effect of low doses of L-NAME on methamphetamine-induced dopaminergic depletion in the rat striatum
EP1758566A2 (fr) Utilisation d'agonistes des recepteurs cb2 dans le traitement de la maladie d'huntington
MXPA99010417A (en) METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS
US3036955A (en) Analgesic 5-lower alkyl-2-amino thiazoles

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)